UPCC 19520: An Open-Label Multi-Institutional Pilot Study to Assess The Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate

Recruiting
99 years or below
All
Phase 1
1 Location

Brief description of study

This study is being done to answer the following question: Does scheduled glucarpidase reduce the levels of methotrexate in patients blood and lead to shorter hospitalizations and a reduction in toxicities? Eligible subjects will be those with osteosarcoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 04 Feb 2021. Study ID: 844853

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.